[1] Young AM, Marshall A, Thirlwall J, Hill C, Hale D, Dunn J, Lokare A, Kakkar AK, Levine MN, Chapman O. Anticoagulation Therapy in Selected Cancer Patients at Risk of Recurrence of Venous Thromboembolism: Results of the Select-D? Pilot Trial. Blood Dec 2017, 130 (Suppl 1) 625.
[2] K?nigsbr?gge O, Pabinger I, Ay C. Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study (CATS).Thromb Res. 2014 May;133 Suppl 2:S39-43. doi: 10.1016/S0049-3848(14)50007-2.
[3] Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, Hale D, Dunn JA, Lyman GH, Hutchinson C, MacCallum P, Kakkar A, Hobbs FDR, Petrou S, Dale J, Poole CJ, Maraveyas A, Levine M. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018 May 10:JCO2018788034. doi: 10.1200/JCO.2018.78.8034. [Epub ahead of print]
Home Young AM, Marshall A
